Recursion Pharmaceuticals Statistics
Total Valuation
RXRX has a market cap or net worth of $2.21 billion. The enterprise value is $1.73 billion.
| Market Cap | 2.21B |
| Enterprise Value | 1.73B |
Important Dates
The next estimated earnings date is Wednesday, November 4, 2026, before market open.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RXRX has 536.27 million shares outstanding. The number of shares has increased by 41.13% in one year.
| Current Share Class | 535.34M |
| Shares Outstanding | 536.27M |
| Shares Change (YoY) | +41.13% |
| Shares Change (QoQ) | +0.60% |
| Owned by Insiders (%) | 2.98% |
| Owned by Institutions (%) | 65.86% |
| Float | 519.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 40.28 |
| Forward PS | 40.44 |
| PB Ratio | 2.41 |
| P/TBV Ratio | 4.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 31.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.03, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.03 |
| Quick Ratio | 4.67 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -371.35 |
Financial Efficiency
Return on equity (ROE) is -56.58% and return on invested capital (ROIC) is -34.57%.
| Return on Equity (ROE) | -56.58% |
| Return on Assets (ROA) | -27.33% |
| Return on Invested Capital (ROIC) | -34.57% |
| Return on Capital Employed (ROCE) | -50.33% |
| Weighted Average Cost of Capital (WACC) | 9.69% |
| Revenue Per Employee | $91,427 |
| Profits Per Employee | -$864,807 |
| Employee Count | 600 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.58M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.22% in the last 52 weeks. The beta is 1.03, so RXRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -19.22% |
| 50-Day Moving Average | 3.42 |
| 200-Day Moving Average | 3.57 |
| Relative Strength Index (RSI) | 61.90 |
| Average Volume (20 Days) | 21,422,000 |
Short Selling Information
The latest short interest is 178.72 million, so 33.33% of the outstanding shares have been sold short.
| Short Interest | 178.72M |
| Short Previous Month | 179.15M |
| Short % of Shares Out | 33.33% |
| Short % of Float | 34.41% |
| Short Ratio (days to cover) | 11.32 |
Income Statement
In the last 12 months, RXRX had revenue of $54.86 million and -$518.88 million in losses. Loss per share was -$1.02.
| Revenue | 54.86M |
| Gross Profit | -392.60M |
| Operating Income | -549.97M |
| Pretax Income | -523.47M |
| Net Income | -518.88M |
| EBITDA | -471.60M |
| EBIT | -549.97M |
| Loss Per Share | -$1.02 |
Balance Sheet
The company has $545.68 million in cash and $66.64 million in debt, with a net cash position of $479.05 million or $0.89 per share.
| Cash & Cash Equivalents | 545.68M |
| Total Debt | 66.64M |
| Net Cash | 479.05M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 915.00M |
| Book Value Per Share | 1.71 |
| Working Capital | 483.58M |
Cash Flow
In the last 12 months, operating cash flow was -$350.48 million and capital expenditures -$1.79 million, giving a free cash flow of -$352.27 million.
| Operating Cash Flow | -350.48M |
| Capital Expenditures | -1.79M |
| Depreciation & Amortization | 78.36M |
| Net Borrowing | -8.75M |
| Free Cash Flow | -352.27M |
| FCF Per Share | -$0.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,002.56% |
| Pretax Margin | -954.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -41.13% |
| Shareholder Yield | -41.13% |
| Earnings Yield | -23.48% |
| FCF Yield | -15.94% |
Analyst Forecast
The average price target for RXRX is $7.22, which is 75.24% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.22 |
| Price Target Difference | 75.24% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 19.15% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RXRX has an Altman Z-Score of 0.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.61 |
| Piotroski F-Score | 3 |